School of Medicine
Showing 161-180 of 624 Results
-
Pascal Geldsetzer
Assistant Professor of Medicine (Primary Care and Population Health) and, by courtesy, of Epidemiology and Population Health
BioPascal Geldsetzer is an Assistant Professor of Medicine in the Division of Primary Care and Population Health and, by courtesy, in the Department of Epidemiology and Population Health. He is also affiliated with the Phil & Penny Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute, Department of Biomedical Data Science, Department of Health Policy, and the Stanford Center for Population Health Sciences.
His research focuses on identifying and evaluating the most effective interventions for improving health at older ages. In addition to leading several randomized trials, his methodological emphasis lies in the use of natural experiments to ascertain causal effects in large observational datasets, particularly in electronic health record data. He has won an NIH New Innovator Award (in 2022), a Chan Zuckerberg Biohub investigatorship (in 2022), and three NIH R01 grants as Principal Investigator (in 2023 and 2024). In 2026, he was named one of the 100 most influential people in health and medicine globally by TIME Magazine. -
Margarita Geleta
Graduate, Biomedical Data Science
BioMargarita Geleta is a computer science PhD student at University of California, Berkeley (major in Artificial Intelligence and minor in Human-Computer Interaction), and a graduate exchange student at Stanford University. Ms. Geleta received her M.S. in computer science at University of California, Berkeley.
-
Linda N. Geng, MD, PhD
Clinical Associate Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly InterestsMy scholarly focus is on puzzling and complex conditions. Our work aims to improve patients' diagnostic journeys, characterize poorly understood diseases, discover biological mechanisms, find treatments, improve care models, and reach communities in need.
With the COVID pandemic, the puzzling and complex illness of Long COVID or post-acute COVID-19 syndrome (PACS) emerged. Together with a multidisciplinary group of physicians and researchers, we launched a program here at Stanford to advance the care and understanding of Long COVID. Our goal is to better understand the natural history, clinical symptomatology, immunological response, risk factors, and subtypes of Long COVID. We are also actively assessing treatment strategies for Long COVID and developing care pathways and tools for clinicians to help their patients with this and other related infection-associated chronic illnesses. -
Grace Gengoux, PhD, BCBA-D
Clinical Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
Current Research and Scholarly InterestsDr. Grace Gengoux is Director of the Autism Intervention Clinic and leads an autism intervention research program focused on developing and evaluating promising behavioral and developmental treatments for Autism Spectrum Disorder (ASD).
Dr. Gengoux is also Associate Chair for Faculty Engagement & Well-being and Department Well-being Director in the Department of Psychiatry and Behavioral Sciences, leading the department's Standing Well-being Advisory Committee. -
Jacqueline Genovese
Academic Prog Prof 3, School of Medicine - Biomedical Ethics
Current Role at StanfordExecutive Director of the Medicine & the Muse Program
LEAD Program for Residents, Mentor (2021-2024)
Member of Stanford School of Medicine Staff Collective
Steering Committee Member: Health Humanities Consortium (2019-2024)
Teaching Lead, War Literature & Writing class for military affiliated students
Co-teacher, War and Fiction for non military and military affiliated students (2017-2109)
Facilitator, Literature & Medicine Dinner & Discussion Series
Co-Lead: Frankenstein@200 2017-2018 Initiative
Member of Stanford Medicine Arts & Mindfulness Committee (Stanford Health) -
Mark Genovese
James W. Raitt M.D. Professor, Emeritus
Current Research and Scholarly InterestsClinical trials and interventions in the rheumatic diseases including Rheumatoid Arthritis,Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis.
-
Michael Gensheimer, MD
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Current Research and Scholarly InterestsIn addition to my clinical research in head and neck and lung cancer, I work on the application of computer science and machine learning to cancer research. I develop tools for analyzing large datasets to improve outcomes and safety of cancer treatment. I developed a machine learning prognostic model using data from around 13,000 patients with metastatic cancer which performs better than traditional models and physicians [PubMed ID 33313792]. We recently completed a prospective randomized study in thousands of patients in which the model was used to help improve advance care planning conversations.
I also work on the methods underpinning observational and predictive modeling research. My open source nnet-survival software that allows use of neural networks for survival modeling has been used by researchers internationally. In collaboration with the Stanford Research Informatics Center, I examined how electronic medical record (EMR) survival outcome data compares to gold-standard data from a cancer registry [PubMed ID 35802836]. The EMR data captured less than 50% of deaths, a finding that affects many studies being published that use EMR outcomes data. -
Andrew Gentles
Associate Professor (Research) of Pathology, of Medicine (Computational Medicine) and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsComputational systems biology
-
Heather Gentner
Director of Finance and Administration (SoM), Stem Cell Bio Regenerative Med Institute
Current Role at StanfordI am the Director of Finance and Administration for the Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM) in the School of Medicine. I oversee and carry out administrative and financial related functions for the department.
-
Paul George, MD, PhD
Associate Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsDEVELOPMENT OF STROKE RECOVERY THERAPEUTICS:
Stroke is devastating to patients and their caregivers. We currently are investigating 3 neural repair approaches. The first focuses on developing a stroke recovery therapeutic based on an essential repair pathway and how it alters the immune response following stroke. The second utilizes implantable, conductive polymer devices to electrically manipulate the recovering nervous system to improve recovery and identify novel therapeutic targets. The final approach works to optimize stem cell therapeutics to enhance their ability to treat patients who have suffered from neural injury.
CONDUCTIVE BIOPOLYMER SYSTEMS FOR NEURAL RECOVERY AND STEM CELL MODULATION:
The George lab develops biomaterials to improve neural recovery in the peripheral and central nervous systems. By controlled release of drugs and molecules through biomaterials we can study the temporal effect of these neurotrophic factors on neural recovery and engineer drug delivery systems to enhance regenerative effects. By identifying the critical mechanisms for neural recovery, we are able to develop polymeric technologies for clinical translation in nerve regeneration. Recent work utilizes these novel conductive polymers to differentiate stem cells for therapeutic and drug discovery applications.
APPLYING ENGINEERING TECHNIQUES TO DETERMINE BIOMARKERS FOR STROKE DIAGNOSTICS:
The ability to create diagnostic assays and techniques enables us to understand biological systems more completely and improve clinical management. Previous work utilized mass spectroscopy proteomics to find a simple serum biomarker for TIAs (a warning sign of stroke). Our study discovered a novel candidate marker, platelet basic protein. Current studies are underway to identify further candidate biomarkers using transcriptome analysis. More accurate diagnosis will allow for aggressive therapies to prevent subsequent strokes.
